Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus aflibercept for eye disease in Sweden (EudraCT 2018-004438-14)
2018-004438-14Phase 2Active
- Sponsor
- Region Västra Götaland
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab and aflibercept in well-being (2 arms), sponsored by Region Västra Götaland. Started May 2019; status: active.
02
Drugs
bevacizumabaflibercept
03
Conditions
well-being
Beyond the preview
Go deeper on 2018-004438-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004438-14.